71 completed, 23 recruiting, 20 terminated, 16 active not recruiting. 149 Phase 1, 54 Phase 2.
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE - Thyroid Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 18 | 2026-11-11 | 2026-11-06 |
| Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) REGN24493, Placebo - Graves' Disease | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 45 | 2026-11-02 | 2026-10-06 |
| Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial Personalised treatment - Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer | Phase 1 | Recruiting | Radboud University Medical Center | 10 | 2026-10-01 | 2026-10-28 |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-26 |
| A Study of IBI3031 in Participants With Thyroid Eye Disease IBI3031, placebo - Thyroid Eye Disease | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 66 | 2026-06-30 | 2026-07-14 |
| A Clinical Study of Cizutamig in Thyroid Eye Disease Cizutamig will be dosed according to the protocol. - Thyroid Eye Disease, TED | Phase 1 | Recruiting | Candid Therapeutics | 38 | 2026-05-08 | 2026-09-01 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| Effects of Different Administration Routes of Dexmedetomidine on Postoperative Sleep Quality in Patients Undergoing Thyroidectomy Dexmedetomidine (DEX), Saline - Thyroid Diseases | Phase 1 / Phase 2 | Completed | The Second People's Hospital of Huai'an | 120 | 2026-01-05 | 2026-09-11 |
| 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer 177Lu-CTR-FAPI therapy - Thyroid Cancer | Phase 1 | Recruiting | SHAOYAN LIU | 12 | 2026-01-01 | 2026-02-27 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation XP-102, Trametinib - Cancer, BRAF V600 Mutation | Phase 1 / Phase 2 | Not yet recruiting | Xynomic Pharmaceuticals, Inc. | 221 | 2025-12-31 | 2025-04-10 |
| NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease MER511 (IV), Placebo comparator (IV), MER511 (SC) - Graves Disease | Phase 1 | Recruiting | Merida Biosciences | 100 | 2025-12-19 | 2026-10-29 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| A Study of DEG6498 in Participants With Solid Tumors DEG6498 - Malignant Neoplasms | Phase 1 | Recruiting | Degron Therapeutics Co. | 100 | 2025-11-13 | 2026-06-30 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants Teprotumumab, Placebo - Healthy Volunteers | Phase 1 | Completed | Amgen | 20 | 2025-08-26 | 2026-02-27 |
| Study of BHV-1300 in Graves' Disease BHV-1300 - Graves Disease | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 15 | 2025-08-21 | 2026-07-31 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
Showing 20 of 149. Sign in to see all of them.
Thyroid Neoplasms (92) · Carcinoma, Non-Small-Cell Lung (37) · Melanoma (35) · Breast Neoplasms (30) · Head and Neck Neoplasms (24) · Neoplasms (24) · Ovarian Neoplasms (24) · Pancreatic Neoplasms (24) · Colorectal Neoplasms (23) · Lung Neoplasms (23) · Prostatic Neoplasms (23) · Thyroid Cancer, Papillary (23) · Graves Ophthalmopathy (21) · Colonic Neoplasms (20) · Sarcoma (20)
Endocrine System Diseases (142) · Neoplasms by Site (101) · Endocrine Gland Neoplasms (96) · Neoplasms (83) · Head and Neck Neoplasms (79) · Neoplasms by Histologic Type (74) · Neoplasms, Glandular and Epithelial (67) · Carcinoma (60) · Skin Diseases (56) · Skin and Connective Tissue Diseases (56) · Neoplasms, Nerve Tissue (54) · Neoplasms, Germ Cell and Embryonal (53) · Neuroectodermal Tumors (53) · Adenocarcinoma (52)
Magnetic Resonance Spectroscopy (5) · teprotumumab (4) · Cetuximab (3) · Cyclophosphamide (3) · Fluorodeoxyglucose F18 (3) · Iodine-131 (3) · Triiodothyronine (3) · pembrolizumab (3) · trametinib (3) · 130-nm albumin-bound paclitaxel (2) · Azacitidine (2) · Bevacizumab (2) · Biopsy (2) · Bortezomib (2) · Cisplatin (2)
National Cancer Institute (NCI) (8) · Amgen (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · Eli Lilly and Company (4) · Exelixis (3) · AHS Cancer Control Alberta (2) · Celgene (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Dana-Farber Cancer Institute (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Hoffmann-La Roche (2) · Jonsson Comprehensive Cancer Center (2) · Pfizer (2) · Sichuan Enray Pharmaceutical Sciences Company (2)
United States (95) · China (25) · Canada (17) · Australia (16) · Spain (14) · France (13) · United Kingdom (11) · Italy (9) · South Korea (9) · Germany (8) · Japan (8) · Denmark (7) · Hong Kong (7) · Netherlands (7) · Taiwan (7)
Anne R Cappola, MD,ScM (2) · Jeremie Calais (2) · Ravinder Grewal, MD (2) · Yun Yen, M.D., Ph.D. (2) · Alan L Ho, MD, PhD (1) · Alexander McEwan, MB, FCRPC (1) · Allison Betof Warner, MD, PhD (1) · Anthony W Tolcher, M.D. (1) · Anthony W. Tolcher, MD (1) · Antoni Ribas, M.D. (1)
PMID 37171634, PMID 37934000, PMID 17985341, PMID 18299459, PMID 19192962, PMID 19372041, PMID 19602035, PMID 19735988, PMID 19850691, PMID 20145168, PMID 20305636, PMID 21367608, PMID 21606412, PMID 22219499, PMID 23489023, PMID 23676418, PMID 23868427, PMID 24827131, PMID 25086465, PMID 26041482, PMID 26163763, PMID 26221138, PMID 26933802, PMID 27240885, PMID 28662033, PMID 28744123, PMID 29186019, PMID 30093503, PMID 30184767, PMID 30261427, PMID 30297385, PMID 31838007, PMID 32269053, PMID 32416981, PMID 32510916, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 34766118, PMID 34965951, PMID 34998048, PMID 35045748, PMID 35340114, PMID 35389070, PMID 35395680, PMID 35715405, PMID 35930972, PMID 35962206
2023 (4), 2016 (3), 2025 (3), R61HL146390 (2), 2017 (1), 2018 (1), 2019 (1), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA008748 (1), P30CA014599 (1)